samedan logo
 
 
spacer
home > pmps > winter 2002 > the scope of validation for cleanroom disinfectants
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Scope of Validation for Cleanroom Disinfectants

The validation of disinfectants for use in controlled environments can be both lengthy and expensive. This article examines the scope of disinfectant validation and how to ensure a smooth and successful outcome. As a disinfectant manufacturer we have a unique perspective on validation as not only do we have an in-depth knowledge of disinfectants but we also operate cleanrooms to the same cGMP standards as pharmaceutical manufacturers. It also allows us to gain a broad range of experience across the many life science fields including the pharmaceutical, biotechnology and medical device industries where similar issues arise repeatedly. The message is simple: consider all aspects of new agents right from the start. This will produce quick and meaningful validation results, which subsequently leads to early implementation of new disinfectants and prompt responses to audits.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Andrew Davidson, Commercial Director of Shield Medicare Ltd
Andrew Davidson is the Commercial Director of Shield Medicare Ltd. His qualifications include a BSc (Hons) in Biological Sciences and a CIM Diploma in Marketing. He has been with Shield Medicare for six years, having been recruited to develop the contamination control business. Before this he worked in the pharmaceutical industry for 15 years in both sales and marketing and product development roles.

spacer
Andrew Davidson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement